Tauopathies reduced, neuronal loss halted with antisense oligonucleotides

Written by Lauren Pulling

Researchers have identified antisense oligonucleotides (ASOs) that are able to decrease human tau deposits and reduce existing tauopathies in transgenic mouse models. In additional, neuronal loss was also prevented and lifespan increased in treated mice, and tau deposits reduced in the brain and CSF in primate models. These significant findings highlight a new therapeutic avenue for the treatment of Alzheimer’s and other neurodegenerative diseases in which tau deposits correlate with disease progression and cognitive decline. The study was carried out by a team comprising researchers from Washington University School of Medicine in St. Louis (MO, USA), University of Texas Southwestern...

To view this content, please register now for access

It's completely free